Anti-cancer potential evaluation of novel Ru(II) and Os(II) complexes with polycyclic aromatic substituents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F24%3AN0000239" target="_blank" >RIV/00027162:_____/24:N0000239 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Anti-cancer potential evaluation of novel Ru(II) and Os(II) complexes with polycyclic aromatic substituents

Popis výsledku v původním jazyce

58TH CONFERENCE ADVANCES IN ORGANIC, BIOORGANICAND PHARMACEUTICAL CHEMISTRY "LIBLICE 2024" SPINDLERUV MLYN - HARMONY CLUB HOTEL, 7 - 9 NOVEMBER 2024 – poster. In our work we introduce new series of half-sandwich Ru(II) and Os(II) complexes with the general formula [M(η6 pcym)Cl(L)]PF6, involving ethane-1,2-diamine-based Schiff bases bearing two terminal polycyclic aromatic hydrocarbon (PAH) substituents (Fig. 1). These complexes were fully characterized (e.g. multinuclear NMR, mass spectrometry or HPLC), and their physicochemical properties, including solution stability and DNA interactions, were examined. The results showed that these complexes are stable in the presence of water under the mimicked physiological conditions. The primary focus of our work was on their biological activities, with potential applications as novel cytostatic agents. The complexes exhibited stronger cytotoxic effects against various lung cancer cell lines, including those resistant to cisplatin (CDDP), when compared to CDDP. Unlike CDDP, these complexes did not cause alterations in the cell cycle but were found to impact mitochondrial function, contributing to cell death Analysis of the expression of stress-related genes revealed the ability of used complexes to induce endoplasmic reticulum stress and oxidative stress. In all cell-based in vitro experiments, Os(II) complexes were more potent than Ru(II) ones. It can be concluded that the studied Ru(II) and Os(II) complexes with PAH substituents represent a promising group of compounds with significant anti-cancer potential and with different mode of action than CDDP.

Název v anglickém jazyce

Anti-cancer potential evaluation of novel Ru(II) and Os(II) complexes with polycyclic aromatic substituents

Popis výsledku anglicky

58TH CONFERENCE ADVANCES IN ORGANIC, BIOORGANICAND PHARMACEUTICAL CHEMISTRY "LIBLICE 2024" SPINDLERUV MLYN - HARMONY CLUB HOTEL, 7 - 9 NOVEMBER 2024 – poster. In our work we introduce new series of half-sandwich Ru(II) and Os(II) complexes with the general formula [M(η6 pcym)Cl(L)]PF6, involving ethane-1,2-diamine-based Schiff bases bearing two terminal polycyclic aromatic hydrocarbon (PAH) substituents (Fig. 1). These complexes were fully characterized (e.g. multinuclear NMR, mass spectrometry or HPLC), and their physicochemical properties, including solution stability and DNA interactions, were examined. The results showed that these complexes are stable in the presence of water under the mimicked physiological conditions. The primary focus of our work was on their biological activities, with potential applications as novel cytostatic agents. The complexes exhibited stronger cytotoxic effects against various lung cancer cell lines, including those resistant to cisplatin (CDDP), when compared to CDDP. Unlike CDDP, these complexes did not cause alterations in the cell cycle but were found to impact mitochondrial function, contributing to cell death Analysis of the expression of stress-related genes revealed the ability of used complexes to induce endoplasmic reticulum stress and oxidative stress. In all cell-based in vitro experiments, Os(II) complexes were more potent than Ru(II) ones. It can be concluded that the studied Ru(II) and Os(II) complexes with PAH substituents represent a promising group of compounds with significant anti-cancer potential and with different mode of action than CDDP.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/NU22-08-00236" target="_blank" >NU22-08-00236: Preklinické studie neplatinových metaloléčiv v terapii rakoviny plic</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů